A Brief Look at Mikhail Blagosklonny and his Passion for Rapamycin
Mikhail Blagosklonny is a scientist who researches on Aging and cancer. He plays the role of a professor of Oncology at the Rosewell Park Cancer Institute. He attained an MD in Internal Medicine at the First Pavlov State Medical University of St. Petersburg. Additionally, he attained a Ph.D. from the First Pavlov State Medical University of St. Petersburg in Experimental Medicine and Cardiology. He was given the position of an associate professor of medicine in the year 2002 in the New York Medical College. The college is situated in Valhalla, New York. Later on, He became a part of the Ordway Research Institute where he played the role of a senior scientist. He became a part of the Roswell Park Cancer Institute in the year 2009 as a Professor in Oncology. The skills and experience he attained in the various locations he worked aided him in becoming a remarkable professor. Some of his research interests consist of cancer, Biogerontology, targeted cancer therapies which protect the cells which are healthy from attaining damage as well as anti-aging drugs.
Mikhail Blagosklonny plays the role of the editor-in-chief for Cell Cycle as well as Oncotarget. Additionally, he plays the role of the associate editor of cancer therapy and biology. Mikhail is also on the editorial board of Differentiation and Death Cell. Mikhail came about a hypothesis concerning TOR Signalling possible part in aging and cancer. Mikhail recommended that this could act as a treatment for lie extension. Mikhail Blagosklonny has been grouped as one of the highly passionate supporters of Rapamycin in the research for longevity. His research consists of molecular biology to cellular to clinical investigations. It mainly has to do with apoptosis, tumor suppressors, ontogenesis, drug resistance for normal cells selective protection, mitosis, anticancer therapeutics, and cell cycle.
Mikhail brought about the theory of aging hyperfunction. He also writes about chemotherapeutic engineering and cell cytotherapy. Additionally, he is recognized for his deep interest in oncology. He is of the belief that the control of cancer and aging can be controlled. He also believes that the cure for cancer is possible and that is why he recommended the utilization of Rapamycin. He has over 200 book chapters, research articles, and reviews accredited to his name. Additionally, Mikhail Blagosklonny plays the role of an associate editor for the International Journal of Cancer, PLOS ONE and the American Journal of Pathology.
Mikhail’s commitment and hard work are part of the things that have assisted in his achievement to becoming one of the largest researchers of Oncology around the globe. He states that the love he possesses for humanity as well as the vision of seeing a community that is free of disease is what pushed him into his line of work.
In the year 2006, it was concluded that Sirolimus or Rapamune which are also known as Rapamycin in basic science have already gotten the required approval to enable them to be used clinically. Additionally, Rapamycin can assist in the treatment of metabolic disorders, autoimmunity and a host of other diseases. Visit ResearchGate.Net to learn more about Mikhail’s latest work.